Insider Trade: Mark Pruzanski Obtained 7,812 Shares of Intercept Pharmaceuticals, Inc. (ICPT); Shorts at AALBERTS INDUSTRIES NV ORDINARY SHARES (AALBF) Lowered By 8.19%

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

AALBERTS INDUSTRIES NV ORDINARY SHARES (OTCMKTS:AALBF) had a decrease of 8.19% in short interest. AALBF’s SI was 131,100 shares in April as released by FINRA. Its down 8.19% from 142,800 shares previously. The SI to AALBERTS INDUSTRIES NV ORDINARY SHARES’s float is 0.14%. It closed at $50.9243 lastly. It is down 0.00% since April 10, 2017 and is . It has underperformed by 11.55% the S&P500.

Aalberts Industries N.V. operates as a technology firm in Western and Northern Europe, North America, Eastern Europe, Southern Europe, the Middle East and Africa, the Far East, and internationally. The company has market cap of $. The firm operates through four divisions: Building Installations, Climate Control, Industrial Controls, and Industrial Services. It currently has negative earnings. The Building Installations segment makes and markets connection systems and valves to distribute and control water or gas in heating, cooling, drinking water, gas, and sprinkler systems in residential, commercial, and industrial buildings and industrial installations.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on May, 3. They expect $-3.42 EPS, up 5.26% or $0.19 from last year’s $-3.61 per share. After $-4.43 actual EPS reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -22.80% EPS growth.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals has $423 highest and $45.0 lowest target. $154.49’s average target is 123.12% above currents $69.24 stock price. Intercept Pharmaceuticals had 73 analyst reports since August 10, 2015 according to SRatingsIntel. As per Monday, February 12, the company rating was maintained by Wedbush. The rating was downgraded by Needham on Friday, January 20 to “Hold”. The firm has “Buy” rating given on Thursday, January 25 by Wedbush. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Outperform” rating given on Friday, December 30 by Wedbush. Morgan Stanley maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Tuesday, May 31 with “Underweight” rating. The firm earned “Market Perform” rating on Thursday, September 21 by Wells Fargo. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Tuesday, June 13. Wedbush has “Buy” rating and $23100 target. The firm earned “Buy” rating on Thursday, June 1 by Credit Suisse. The stock has “Strong-Buy” rating by Vetr on Thursday, September 17. The stock has “Underperform” rating by Morgan Stanley on Friday, April 8.

The stock decreased 3.30% or $2.36 during the last trading session, reaching $69.24. About 796,424 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 48.35% since April 10, 2017 and is downtrending. It has underperformed by 59.90% the S&P500.

Mark Pruzanski, the CEO & President of Intercept Pharmaceuticals Inc, purchased 7,812 shares of the company, with market value of roughly $499,968 U.S Dollars, which is based on a market stock price of $64.0 per share. This trade was reported on 09-04-2018 and is already filed with the Security and Exchange Commission. The source Form 4 is ready for review to the public here. Mr. Mark at present holds 576,564 shares, accounting for 2.29% of the Company’s stock market capitalization.

Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.02, from 1.33 in 2017Q3. It dropped, as 19 investors sold Intercept Pharmaceuticals, Inc. shares while 42 reduced holdings. 36 funds opened positions while 44 raised stakes. 17.97 million shares or 1.43% less from 18.23 million shares in 2017Q3 were reported. Credit Suisse Ag holds 155,657 shares or 0.01% of its portfolio. Tiaa Cref Inv Ltd Liability Corporation invested in 62,211 shares or 0% of the stock. Wells Fargo & Mn owns 66,360 shares or 0% of their US portfolio. Atlantic Tru Lc has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Fmr Limited Liability Company has invested 0.03% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Clearbridge Ltd Limited Liability Company holds 0% or 843 shares. 115,679 are owned by Emerald Mutual Fund Advisers Tru. Moreover, Janney Montgomery Scott Llc has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Price T Rowe Md accumulated 8,753 shares or 0% of the stock. Exane Derivatives accumulated 0.01% or 950 shares. 14,879 are held by Bnp Paribas Arbitrage. 8,390 were reported by Dekabank Deutsche Girozentrale. Ameriprise Fin accumulated 151,782 shares. 14,004 are owned by Proshare Advisors Ltd Liability Com. Virtu Ltd Liability Corporation invested in 4,003 shares or 0.01% of the stock.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $1.74 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart